CN113648392A - Traditional Chinese medicine composition for treating cerebral infarction - Google Patents
Traditional Chinese medicine composition for treating cerebral infarction Download PDFInfo
- Publication number
- CN113648392A CN113648392A CN202110803584.6A CN202110803584A CN113648392A CN 113648392 A CN113648392 A CN 113648392A CN 202110803584 A CN202110803584 A CN 202110803584A CN 113648392 A CN113648392 A CN 113648392A
- Authority
- CN
- China
- Prior art keywords
- parts
- cerebral infarction
- traditional chinese
- chinese medicine
- treating cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 206010008118 cerebral infarction Diseases 0.000 title claims abstract description 23
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 11
- 241000218176 Corydalis Species 0.000 claims abstract description 8
- 235000002710 Ilex cornuta Nutrition 0.000 claims abstract description 8
- 241001310146 Ilex cornuta Species 0.000 claims abstract description 8
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 claims abstract description 8
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 7
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 7
- 241001013934 Erigeron breviscapus Species 0.000 claims abstract description 7
- 241000304531 Allium macrostemon Species 0.000 claims abstract description 6
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 5
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 5
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 5
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 5
- 244000302909 Piper aduncum Species 0.000 claims abstract description 5
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 5
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 235000019509 white turmeric Nutrition 0.000 claims abstract description 5
- 241000915604 Scutellaria barbata Species 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000009609 fructus phyllanthi Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 241001523681 Dendrobium Species 0.000 abstract description 2
- 240000001398 Typha domingensis Species 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 208000006011 Stroke Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000008496 Drimys aromatica Nutrition 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 244000134857 Typha capensis Species 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating cerebral infarction, which is prepared from the following raw material medicines in parts by weight: safflower, cattail pollen, emblic leafflower fruit, longstamen onion bulb, corydalis amabilis, dendrobium, wild pepper, erigeron breviscapus, tabasheer, Chinese holly leaf, barbed skullcap herb, zedoary and glossy privet fruit. The invention has the characteristics of obvious treatment effect, short treatment period, no toxic or side effect and the like.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating cerebral infarction.
Background
Cerebral infarction is the most common type of cerebral infarction. Atherosclerosis of main or cortical branch of cerebral artery causes thickening of blood vessel, narrow and blocked lumen and thrombosis, which causes reduction of local blood flow or blood supply interruption of brain, and ischemia and anoxia of brain tissue causes softening necrosis and occurrence of focal nervous system symptoms.
The life quality of patients with cerebral infarction sequelae is obviously reduced due to the lasting limb disabilities and language barriers, and the patients are often accompanied and cared by family members. The traditional treatment method of the cerebral infarction sequela is rest by bed without specific drug treatment, so that most of patients with the cerebral infarction sequela lose the chance of recovery and recovery, and permanently remain the disabled limbs or even die.
Disclosure of Invention
The invention aims to improve the defects of the prior art and provides the traditional Chinese medicine composition for cerebral infarction, which has the characteristics of obvious treatment effect, short treatment period, no toxic or side effect and the like.
Cerebral infarction belongs to the category of stroke in traditional Chinese medicine, and is the first of four major difficult symptoms in traditional Chinese medicine, and sequelae such as hemiplegia, language disorder and the like are remained. The theory of stroke originates from the "Nei Jing" (Nei Jing), which is formed in the "jin Kui Yao L ü e", and physicians in past generations believe that brain marrow is damaged by wind, fire, phlegm, blood stasis, toxin and blood stasis blocking brain collaterals and endogenous toxin removal of all pathogenic factors. Therefore, the applicant believes that the treatment of cerebral infarction should be effective in resisting platelet aggregation, resisting atheromatous plaque formation, enhancing blood flow in brain tissue, reducing cerebral vascular resistance, improving blood brain barrier permeability, alleviating cerebral edema, alleviating metabolic disorders of monoamine neurotransmitters in brain tissue, and restoring or approaching normal decreased neurotransmitters.
Based on the theory, the technical scheme of the invention is as follows: an oral traditional Chinese medicine for treating cerebral infarction comprises the following raw material medicines in parts by weight: 4-8 parts of safflower; pollen typhae, emblic leafflower fruit, longstamen onion bulb and zedoary 5-10 parts; corydalis amabilis, dendrobe, wild pepper and glossy privet fruit 6-12 parts; erigeron breviscapus, tabasheer and 9-18 parts of Chinese holly leaves; 15-30 parts of sculellaria barbata.
In a preferred embodiment, the traditional Chinese medicine composition for treating cerebral infarction consists of the following raw material medicines in parts by weight: 8 parts of safflower; pollen Typhae, fructus Phyllanthi, Bulbus Allii Macrostemi, and Curcumae rhizoma 10 parts; corydalis amabilis, dendrobe, wild pepper and glossy privet fruit 12 parts; erigeron breviscapus, tabasheer and Chinese holly leaf 18 parts; 30 parts of barbed skullcap herb.
Wherein, the erigeron breviscapus: pungent, slightly bitter and warm. Dispel cold, relieve exterior syndrome, dispel wind, activate collaterals, and relieve pain due to dampness. Erigeron breviscapus has obvious effect of expanding middle cerebral artery, and can lower cerebral vascular tension, peripheral vascular resistance and peripheral blood pressure obviously. Clinical observation shows that the medicine has obvious curative effect on paralysis caused by cerebrovascular accident.
Rhizoma corydalis Decumbentis: bitter, slightly pungent and warm. It enters liver meridian. Promote blood circulation to remove meridian obstruction, promote qi circulation to relieve pain. Can be used for treating apoplexy and hemiplegia. Rhizoma corydalis Decumbentis can increase blood flow of brain and lower limbs and reduce vascular resistance. And can be used for resisting the tension of blood vessels of cerebral vessels and lower limbs. The decumbent corydalis tuber total alkaloid obviously inhibits platelet aggregation, obviously inhibits the formation of thrombus and platelet adhesion, and has obvious inhibiting effect on the formation of thrombus.
Cattail pollen: sweet and slightly pungent in flavor; the nature is mild. Liver diseases entering; a core; spleen meridian. Hemostasis is carried out; removing blood stasis; and (4) promoting urination. After the pollen Typhae water extract is taken for 2-5 hours, the dissolving activity of blood fiber is obviously enhanced, and the dissolving rate of thrombus is obviously increased after 24 hours.
Dendrobe: sweet and slightly cold. It enters stomach and kidney meridians. To nourish stomach, promote the production of body fluid, nourish yin and clear heat. The dendrobium contains ester components, has the effects of promoting blood circulation, removing blood stasis, expanding blood vessels and resisting platelet coagulation, and has obvious and definite curative effects on cerebral infarction, arteriosclerotic occlusion and the like.
Mountain pepper: pungent in nature and taste; and (4) warming. Entering the lung; the stomach meridian. Warming middle energizer to dispel cold; promoting qi circulation and relieving pain; relieving asthma. Has obvious curative effect on treating aphasia caused by apoplexy.
And (3) allium macrostemon: pungent, bitter and warm. It enters lung, stomach and large intestine meridians. Regulating qi and relieving chest stuffiness; activate yang and dissipate nodulation, move qi and remove stagnation. After the allium macrostemon alcohol extract is taken for 3 weeks, the activity of platelet adenylate cyclase can be enhanced, the cAMP endogenous level can be increased, the synthesis of TXA2 by platelets can be inhibited, the platelet aggregation can be inhibited, the formation of atheromatous plaques can be obviously inhibited, and the allium macrostemon alcohol extract has good effect of preventing and treating thrombotic vascular diseases.
Barbed skullcap herb: pungent, bitter and cold. It enters lung, liver and kidney meridians. Clearing away heat and toxic material, dispersing blood stasis and promoting urination. The herba Scutellariae Barbatae has effects in increasing cerebral blood flow, reducing cerebrovascular resistance, improving blood brain barrier permeability, and resisting blood platelet aggregation.
Emblic leafflower fruit: sweet, sour, astringent and cool. It enters lung and stomach meridians. Clear heat and cool blood, promote digestion and invigorate stomach, promote the production of body fluid and relieve cough. The emblic leafflower fruit has strong lipid peroxidation resistance, can improve the oxidation resistance of organisms, and has the function of protecting vascular endothelium.
Safflower: pungent and warm. It enters heart and liver meridians. Promoting blood circulation, dredging channels, removing blood stasis and relieving pain. The safflower can expand branch circulation, increase blood flow of cerebral ischemia area, obviously relieve cerebral edema, relieve metabolism disorder of monoamine neuroedium in brain tissue, and make declined neuroedium return to normal or close to normal.
Chinese holly leaf: chinese holly leaf: bitter and cool. It enters liver and kidney meridians. Clear heat, nourish yin, pacify liver, tonify kidney. The Chinese holly leaf has strong activities of enhancing the blood flow of brain tissues, resisting cerebral ischemic injury and the like.
Bamboo yellow: light taste; pungent taste; and (7) flattening. Entering the lung; the liver meridian. Clear heat and eliminate phlegm, cool heart and calm convulsion. Has obvious curative effect on apoplexy, phlegm and aphasia.
Glossy privet fruit: sweet, bitter and cool. It enters liver and kidney meridians. Nourishing liver and kidney, improving eyesight and blackening hair. Can be used for treating vertigo, tinnitus, soreness of waist and knees, premature gray hair, and dim eyesight. 6-12 g. Fructus Ligustri Lucidi can significantly reduce serum total cholesterol, lipid peroxide, and arterial wall total cholesterol, and reduce aortic lipid plaque and coronary atherosclerotic plaque.
Zedoary turmeric: pungent, bitter and warm in flavor. It enters liver and spleen meridians. Move qi and break blood, resolve food stagnation and alleviate pain. The curcuma zedoary has the functions of increasing arterial blood flow, promoting angiogenesis and repairing tissues, and can increase the peak value of the blood flow by 252 percent, increase the blood flow by 36.0 percent after being taken for 10 minutes and reduce the vascular resistance by 66.4 percent.
The Chinese medicinal composition for treating the cerebral infarction is prepared from Chinese traditional Chinese medicinal herbs, and is prepared by orderly matching certain natural extracts with determined components and clear effects according to a plurality of principles of traditional Chinese medicine treatment based on syndrome differentiation and modern medicine.
The invention can be applied throughout the whole process of cerebral infarction treatment, one dose of the prescription is used for treatment, 100 ml of water is decocted by 150ml each day and is divided into two parts, one part is taken in the morning and at night, the effect is obvious, both the symptoms and root causes are treated, the effect is quick, the prognosis effect is good, the recurrence is not easy, the medicine is safe and reliable, no obvious toxic or side effect is caused, the medicine is convenient for patients to insist on taking for a long time, the medicine is taken for many years, the patients have no adverse reaction, and the blood examination is tracked to be normal.
The traditional Chinese medicine composition has the advantages of small number of medicines, easily obtained raw materials, simple process, low cost and high efficiency, and is beneficial to pharmaceutical enterprises to carry out medicine production and quality control; the product has low price and is easy to be accepted by patients.
The treatment cost of the invention is relatively low and is far lower than that of western medicine.
The invention also provides an oral preparation prepared from the traditional Chinese medicine composition for treating cerebral infarction, which comprises oral liquid, tablets, capsules, pills and the like, preferably the dosage forms are tablets and capsules, and one dose is taken every day in the morning and at night.
The traditional Chinese medicine composition can be prepared into various dosage forms. For example, the decocted liquid medicine is sterilized and disinfected and then packaged to prepare oral liquid; or concentrating the decoction, oven drying, adding pharmaceutically acceptable adjuvants, and making into tablet, capsule, pill, etc.
The medically acceptable auxiliary materials comprise starch, dextrin, sodium carboxymethylcellulose, polyethylene glycol, calcium hydrophosphate, sodium alginate, potassium sorbate and the like.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the present invention in any way, and it will be apparent to those skilled in the art that the above description of the present invention can be applied to various modifications, equivalent variations or modifications without departing from the spirit and scope of the present invention.
Claims (4)
1. A traditional Chinese medicine composition for treating cerebral infarction is characterized by comprising the following components: 4-8 parts of safflower; pollen typhae, emblic leafflower fruit, longstamen onion bulb and zedoary 5-10 parts; corydalis amabilis, dendrobe, wild pepper and glossy privet fruit 6-12 parts; erigeron breviscapus, tabasheer and 9-18 parts of Chinese holly leaves; 15-30 parts of sculellaria barbata.
2. The traditional Chinese medicine for treating cerebral infarction according to claim 1 is characterized by comprising the following raw material medicines in parts by weight: 8 parts of safflower; pollen Typhae, fructus Phyllanthi, Bulbus Allii Macrostemi, and Curcumae rhizoma 10 parts; corydalis amabilis, dendrobe, wild pepper and glossy privet fruit 12 parts; erigeron breviscapus, tabasheer and Chinese holly leaf 18 parts; 30 parts of barbed skullcap herb.
3. An oral preparation for treating cerebral infarction, which is prepared from the traditional Chinese medicine composition of any one of claims 1 or 2.
4. The oral preparation for treating cerebral infarction according to claim 3, which is characterized by comprising oral liquid, tablets, capsules and pills, preferably capsules and tablets.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010792314.5A CN111701002A (en) | 2020-08-09 | 2020-08-09 | Traditional Chinese medicine composition for treating cerebral infarction |
| CN2020107923145 | 2020-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113648392A true CN113648392A (en) | 2021-11-16 |
Family
ID=72546997
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010792314.5A Pending CN111701002A (en) | 2020-08-09 | 2020-08-09 | Traditional Chinese medicine composition for treating cerebral infarction |
| CN202110803584.6A Pending CN113648392A (en) | 2020-08-09 | 2021-07-16 | Traditional Chinese medicine composition for treating cerebral infarction |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010792314.5A Pending CN111701002A (en) | 2020-08-09 | 2020-08-09 | Traditional Chinese medicine composition for treating cerebral infarction |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111701002A (en) |
-
2020
- 2020-08-09 CN CN202010792314.5A patent/CN111701002A/en active Pending
-
2021
- 2021-07-16 CN CN202110803584.6A patent/CN113648392A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111701002A (en) | 2020-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111803593A (en) | Antiviral traditional Chinese medicine composition, preparation method and application thereof | |
| CN103877429B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of sinusitis | |
| CN103623280B (en) | A kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease | |
| CN106994141B (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof | |
| CN104857210A (en) | Traditional Chinese medicine combination preparation for treating fatty liver and preparation method thereof | |
| US20030143289A1 (en) | Herbal composition PHY828 and its use | |
| CN113648392A (en) | Traditional Chinese medicine composition for treating cerebral infarction | |
| CN113413431A (en) | Traditional Chinese medicine formula for preventing and treating hypertension | |
| CN112494550A (en) | A Chinese medicinal composition for relieving hangover and treating alcoholic liver | |
| CN113181258A (en) | A Chinese medicinal composition for treating menoxenia, dysmenorrhea, and amenorrhea | |
| CN113144076A (en) | Traditional Chinese medicine composition for treating myocarditis | |
| CN107260978B (en) | Traditional Chinese medicine composition for treating hypertension and preparation method and application thereof | |
| CN111420013A (en) | A Chinese medicinal composition for treating cholecystitis, cholangitis and cholelithiasis | |
| CN116019885A (en) | A Chinese medicinal composition for treating vasculitis and varicosis | |
| CN111494512A (en) | A Chinese medicinal composition for treating coronary heart disease and angina pectoris | |
| CN108478706A (en) | It is a kind of to protect cardiovascular composition and preparation method thereof | |
| CN105477171A (en) | Capsule used for treating hyperlipemia and preparation method of capsule | |
| CN105687779A (en) | Cough and asthma relieving particle and preparation method thereof | |
| CN105288422A (en) | Traditional Chinese medicine preparation used for treating eilema syndromes and preparation method | |
| CN111714601A (en) | A Chinese medicinal composition for treating fungal infection | |
| CN118105442A (en) | Pharmaceutical composition for treating high fever unconsciousness and inducing resuscitation | |
| CN113713027A (en) | Traditional Chinese medicine composition for treating epilepsy | |
| CN111529615A (en) | Traditional Chinese medicine composition for treating rheumatic heart disease | |
| CN111700951A (en) | Chinese medicinal composition for treating abdominal mass | |
| CN117562155A (en) | Health tea with liver protecting effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211116 |